Rueters Trading Alert - 8/29/13
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The Phase I study does not effect ARNA sales and Jefferies says he remains a buyer. The firm views the Belviq label as a huge positive especially since it lacks restrictive REMS or cardiovascular monitoring requirements. Jefferies maintains a Buy rating on the stock.
I do admire Thomas Wei, the Jeffries analyst, he's about the only good biotech analyst and have forgotten more than AF knows. Glad he is in our sinking ship, we need to plug some holes fast, the water is rising.
100% agree ---- and when we get dtc adds going on our numbers should grow by leaps and bounds -- its my personal opinion that at least 85 % of the general public has not even heard the word belviq as of today !!
Sentiment: Strong Buy